Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age

Condition(s) studied

Investigational drug(s) / intervention(s)

Parameters of vascular stiffness: VICORDER© is a noninvasive, quick and painless technique to be able to assess vascular elasticity and consists of placing a few sphygmomanometers (the same ones used to measure blood pressure) for a few minutes

Study summary

To test whether the implementation of new diagnostic techniques (ultrasonography, speckle tracking, vascular stiffness study, cardiac MRI, and histologic studies) allows in CAYA (Childern, Adolescents, and Young Adults) cancer survivors a more sensitive and earlier identification of cardiovascular damage resulting from antineoplastic therapy that develops either acutely or remotely after completion of antineoplastic therapy.

Eligibility

Primary outcome measure(s)

• Incidence of cardiovascular events in CAYA cancer survivors during treatment and follow-up — From initiation of antineoplastic therapy up to 12 months post-therapy
  Number of cardiovascular events, defined according to ESC 2022 guidelines (Eur Heart J. 2022;43:4229-4361), detected during treatment and follow-up. Time to occurrence of events will be measured relative to pre-treatment evaluation.

Trial sites (5)

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy